Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | MMP14 | P50281 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4768354 | 0.76 | CTSB (0.34) | MEN1ALDH1A1KMT2ASMN1; SMN2HTT | |
| SCHEMBL6213890 | 0.76 | CTSB (0.34) | MEN1ALDH1A1KMT2ASMN1; SMN2HTT | |
| SCHEMBL4765372 | 0.70 | GLA (0.37) | SMN1; SMN2 | |
| SCHEMBL6211933 | 0.70 | GLA (0.37) | SMN1; SMN2 | |
| SCHEMBL4315427 | 0.70 | MAPK1 (0.40) | ALDH1A1HTTNPSR1MMP13 | |
| SCHEMBL6256808 | 0.68 | — | — | |
| SCHEMBL4763259 | 0.67 | CTSD (0.44) | MEN1ALDH1A1KMT2AHTT | |
| SCHEMBL6590713 | 0.61 | PSEN1 (0.31) | ALDH1A1 | |
| SCHEMBL6212033 | 0.58 | EPHX1 (0.39) | MEN1KMT2A | |
| SCHEMBL28770859 | 0.57 | MAPT (0.45) | MEN1ALDH1A1KMT2AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307203-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-08-17 | — | — | EP | claimed |
| EP-1307203-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-07 | — | — | EP | claimed |
| WO-2001070232-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-27 | — | — | WO | claimed |
| EP-1320370-A4 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1307203-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1320370-A1 | METHOD OF TREATMENT | SmithKline Beecham Corporation (US) | 2003-06-25 | — | — | EP | disclosed |
| EP-1307203-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002017924-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-03-07 | — | — | WO | disclosed |
| WO-2001070232-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-27 | — | — | WO | disclosed |